Delivery Order SPE2DB22D1002-SPE2DB25FLGR9
- Not listed
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $10,864.83 to AmerisourceBergen Drug Corp for the supply of Rexulti (aripiprazole) 1 mg tablets in a 30-count package. This is a firm fixed-price delivery order with no set-aside designation, awarded on August 20, 2025, and scheduled for completion by August 21, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $4,508.41 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count package) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within the company's extensive pharmaceutical distribution portfolio for federal medical procurement. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency awarded a $18,143.92 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 9, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under a larger vehicle...
- The Defense Logistics Agency awarded a $4,729.87 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 1 mg on August 12, 2025, with completion scheduled for August 13, 2025. This competitive award utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger federal contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order valued at $15,422.40 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 0.5 mg on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract requires delivery to AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order valued at $23,256.95 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. This non-set-aside award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a pharmaceutical delivery to support federal medical procurement needs. The contract is executed from AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLGR9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,278.42 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and serves as a major distributor for federal medical procurement needs. This delivery order represents a child award under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Rexulti, an atypical antipsychotic used in treating schizophrenia and depression, is consistent with the specialized pharmaceutical products AmerisourceBergen provides through its federal contract portfolio to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/21/25 |